References
- Barlogie B., Alexanian R., Smallwood L., et al. Prognostic factors with high‐dose melphalan for refractory multiple myeloma. Blood 1988; 72: 2015–2019, 1988
- Cunningham D., Paz‐Ares L., Gore N. E., et al. High‐dose melphalan for multiple myeloma: Long‐term follow‐up data. J. Clin. Oncol. 1994; 12: 764–768
- Lokhorst H. M., Meuwissen O. J. A., Verdonck L. F., Dekker A. W. High‐risk multiple myeloma treated with high‐dose melphalan. J. Clin. Oncol. 1992; 10: 47–51
- Jagannath S., Vesole D., Glenn L., Crowley J., et al. Low‐risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
- Attal M., Huguet F., Schlaifer D., et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130–1136
- Fermand J., Chevret S., Ravaud P., et al. High‐dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 1993; 82: 2005–2009
- Harousseau J., Milpied N., Laporte J., et al. Double‐intensive therapy in high‐risk multiple myeloma. Blood 1992; 79: 2827–2833
- Dimopolous M., Alexanian R., Przepiorka D., et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high‐risk multiple myeloma. Blood 1993; 82: 2324–2328
- Barlogie B., Jagannath S., Vesole D., et al. Total therapy for newly diagnosed multiple myeloma. Blood 1993; 82(suppl. 1)198a, abstr
- Cunningham D., Paz‐Ares L., Milan S., et al. High‐dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol. 1994; 12: 759–763
- Haas R., Mohle R., Fruhauf S., et al. Patients characteristics associated with successful mobilizing and auto‐grafting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794
- Tricot G., Jagannath S., Vesole D., et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596
- Negrin R., Kusnierz‐Glaz C., Still B., et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non‐Hodgkin's lymphoma. Blood 1995; 85: 3334–3341
- Sheridan W., Begley C., Juttner C., et al. Effect of peripheral‐blood progenitor cells mobilized by filgrastim (G‐CSF) on platelet recovery after high‐dose chemotherapy. Lancet 1992; 339: 640–644
- Gianni A., Bregni M., Stern A., et al. Granulocyte‐macrophage colony‐stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585
- Juttner C., Fibbe W., Nemunaitis J., et al. Blood cell transplantation: report from an international consensus meeting. Bone Marrow Transplantation 1994; 14: 689–693
- Gazitt Y., Reading C., Hoffman R., et al. Purified CD34+ Lin‐ Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381–389
- Gazitt Y., Tian E., Barlogie B., et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte‐macrophage colony‐stimulating factor. Blood 1996; 87: 805–811
- Hillyer C. Large volume leukapheresis to maximize peripheral blood stem cell collection. J. of Hematotherapy 1993; 2: 529–532
- Vesole D., Tricot G., Jagannath S., et al. Auto‐transplants in multiple myeloma: what have we learned?. Blood 1996; 88: 838–847
- Passos‐Coelho J., Braine H., Wright S., et al. Large‐volume leukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J. of Hematotherapy 1995; 4: 11–14
- Desikan K. R., Jagannath S., Vesole D., et al. Collection of peripheral blood stem cells (PBSC) in multiple myeloma (MM) following G‐CSF with or without high‐dose cyclophosphamide. Blood, 86: 402a